nAMD: Why Anatomical Outcomes Matter

Program Overview

PIER Study: Anatomical Measures as Predictors of VA in Ranibizumab-Treated Eyes

Brolucizumab Achieved Superior Reductions in CST From Baseline to Week 16 and Week 48; This Difference Was Maintained at Week 96

HAWK and HARRIER: Study Design

Fewer Patients on Brolucizumab 6 mg Had Disease Activity at Week 16, as Assessed by a Masked Investigator

In Both HAWK and HARRIER, Fewer Patients on Brolucizumab Had IRF and/or SRF at Weeks 16, 48, and 96

In Both HAWK and HARRIER, Fewer Patients on Brolucizumab Had Sub-RPE Fluid at Weeks 16, 48, and 96

Percentage of Patients Never Fluid-Free (Presence of IRF and/or SRF at All Visits) up to Week 48 and Week 96 Were Fewer With Brolucizumab

Points to Consider

Patient Case Presentation

Patient Case (cont)

Patient Case (cont)

Patient Case (cont)

Patient Case (cont)

Patient Case (cont)

Patient Case (cont)

Patient Case (cont)

Patient Case (cont)

Points for Discussion

HAWK/HARRIER: Study Design Week 12 to 16 Assessment

HAWK/HARRIER: Mean CST Change Over Weeks 12 to 16

Patients Treated With Brolucizumab Showed Less CST Increase Over Week 12 to 16: ≥ 75 µm Threshold Stratification

Fewer Patients on Brolucizumab 6 mg Had Disease Activity at Week 16, as Assessed by a Masked Investigator

Significance of Subretinal Fluid

Patient Case Presentation

Patient Case (cont)

Patient Case Presentation: Persistent Intraretinal Fluid

Patient Case (cont)

Patient Case (cont)

Patient Case (cont)

Patient Case (cont)

Concluding Remarks

Abbreviations

Abbreviations (cont)